“Biocon Biologics has continued its growth momentum and delivered a nearly 100% year-on-year revenue growth. This is largely driven by the acquisition of Viatris’ biosimilars business and the growth in market shares for our products in the U.S. and Europe, as we win new customers.
The robust demand for our Insulins portfolio in Emerging Markets will continue to drive growth in these markets and expand access to affordable life-changing treatments.” said Shreehas Tambe, CEO & MD, hashtag BioconBiologics on hashta Q2FY24 results
